{
    "id": 26075,
    "fullName": "PAX3 - FOXO1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PAX3-FOXO1 results from the fusion of PAX3 and FOXO1 (PMID:24334454), resulting in upregulation of downstream target RASSF4, which leads to inhibition of cellular senescence, increased cell proliferation, and inhibition of MST1, a regulator of the Hippo signaling pathway (PMID: 24334454).",
            "references": [
                {
                    "id": 7897,
                    "pubMedId": 24334454,
                    "title": "Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24334454"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5077,
        "geneSymbol": "PAX3",
        "terms": [
            "PAX3",
            "CDHS",
            "HUP2",
            "WS1",
            "WS3"
        ]
    },
    "variant": "PAX3 - FOXO1",
    "createDate": "02/20/2017",
    "updateDate": "02/20/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2308,
                "geneSymbol": "FOXO1",
                "terms": [
                    "FOXO1",
                    "FKH1",
                    "FKHR",
                    "FOXO1A"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11649,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 reduced PAX3-FOXO1 directed transcriptional activity and inhibited growth of alveolar rhabdomyosarcoma (RMS) cell lines harboring PAX3-FOXO1 in culture, and inhibited tumor growth in PAX3-FOXO1-positive alveolar RMS cell line and patient-derived xenograft (PDX) models (PMID: 28446439).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9685,
                    "pubMedId": 28446439,
                    "title": "PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK525762 inhibited growth of alveolar rhabdomyosarcoma cell lines harboring PAX3-FOXO1 in culture (PMID: 28446439).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9685,
                    "pubMedId": 28446439,
                    "title": "PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10014,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DIM-C-pPhCO2Me treatment in an alveolar rhabdomyosarcoma cell line resulted in decreased cell migration in culture and decreased PAX3-FOXO1 expression and reduced metastasis in xenograft models (PMID: 27864345).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 5345,
                "therapyName": "DIM-C-pPhCO2Me",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7908,
                    "pubMedId": 27864345,
                    "title": "PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27864345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Birabresib (OTX015) inhibited growth of alveolar rhabdomyosarcoma cell lines harboring PAX3-FOXO1 in culture (PMID: 28446439).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9685,
                    "pubMedId": 28446439,
                    "title": "PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20032,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "PAX3-FOXO1 fusions aid the diagnosis of alveolar rhabdomyosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 27223,
                "profileName": "PAX3 - FOXO1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4051,
                "name": "alveolar rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rhabdomyosarcoma cell lines with high FGFR4 expression due to a PAX3-FOXO1 fusion demonstrated sensitivity to growth inhibition by H3B-6527 in culture (PMID: 29247039).",
            "molecularProfile": {
                "id": 28909,
                "profileName": "PAX3 - FOXO1 FGFR4 over exp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27223,
            "profileName": "PAX3 - FOXO1",
            "profileTreatmentApproaches": [
                {
                    "id": 14685,
                    "name": "BET  Inhibitor (Pan)",
                    "profileName": "PAX3 - FOXO1"
                }
            ]
        },
        {
            "id": 28909,
            "profileName": "PAX3 - FOXO1 FGFR4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}